Boston Scientific: Q3 Earnings Snapshot

Boston Scientific (BSX) reported Q3 profit of $582M, or 40 cents per share, with adjusted EPS of 73 cents, matching estimates. Revenue was $5.14B, exceeding forecasts. The company expects Q4 EPS of 77-79 cents and full-year EPS of $3.16-$3.18. Shares are down 54% YTD.

Original reporting
Published Oct 28, 2026, 6:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$BSXBullishHigh
01

Why it matters

The earnings beat provides a fresh catalyst for short‑term trading, while guidance tempers long‑term enthusiasm.

02

Market read

First report of Q3 earnings with beat on profit and revenue; actionable for traders.

03

What to watch

Potential headwinds from supply chain or regulatory issues not addressed in the release.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Boston Scientific is a leading medical device maker; its quarterly results are closely watched by healthcare investors.

Company-level read

Ticker impact

$BSXBullishHigh confidence
Context

Boston Scientific reported Q3 profit of $582M and revenue of $5.14B, both beating Zacks estimates.

Expected impact

likely modest upward pressure as market prices in the beat, but guidance may cap gains

Evidence & confidence

Beat on both earnings and revenue provides fresh positive data; guidance is only slightly above expectations, so impact may be limited.

Market effects

Medical device sector may see slight uplift from a large-cap beat.

U.S. healthcare stocks could experience modest gains.

Limited to investors tracking U.S. med‑tech earnings.

Counterpoint

Guidance remains modest; investors may short on expectations of limited upside.

Key entities

  • Boston Scientific Corp.

    Medical device manufacturer reporting Q3 results.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.